Keywords
Asthma
Asthma Control Test and Asthma Control Questionnaire (ACT)
Eosinophils
Exhaled fraction of nitric oxide
Inhaled corticosteroids
Quality life
How to Cite
Abstract
OBJECTIVE: To evaluate the type and intensity of response to benralizumab and identify responders and super-responders amongst patients with severe uncontrolled eosinophilic asthma managed in Mexico.
METHODS: A multicenter study in 3 hospitals in Mexico evaluating the Asthma Control Test and Asthma Control Questionnaire (ACT) scores; mini Asthma Quality of Life Questionnaire; peripheral blood eosinophils; exhaled fraction of nitric oxide; forced expiratory volume in 1 second before and after benralizumab treatment and the number of exacerbations at 12 months.
RESULTS: The record of 28 patients with severe uncontrolled eosinophilic asthma were included. At 12-months, 82.1% were considered in asthma control, where 82% were responders and 64% classified as super-responders. 75% of patients had no exacerbations, with ACT scores improvement in 89% and 79% of patients discontinued maintenance corticosteroids. A total of 82% presented forced expiratory volume in 1 second values over 500 ml. ACT scores showed an average decrease of 1.35 points and a statistically significant decrease in serum eosinophils was observed.
CONCLUSION: This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment.
KEYWORDS: Benralizumab; Asthma; Asthma Control Test and Asthma Control Questionnaire (ACT); Eosinophils; Exhaled fraction of nitric oxide; Corticosteroids; Quality life.
References
1. Mendoza-Cano O, Murillo-Zamora E. Assessing the asthma-related burden of disease in Latin American and Caribbean countries: a sociodemographic perspective. Public health. 2024; (227): 163-168.
2. INEGI. [Asthma, a disease related with poor air quality] [Online]; 2021 [cited 2024 04 04. Available from: https://www.gob.mx/semarnat/articulos/asma-enfermedad-relacionada-con-la-mala-calidad-del-aire
3. Venancio-Hernández M, Mendieta-Flores E, Mendiola-Marín J, et a. Abordaje diagnóstico del asma difícil de tratar y asma grave [The diagnostic approach to difficult-to-treat asthma and severe asthma]. Rev Allerg Mex. 2022; (Suppl 1): s94-s111.
4. Reddel H, Bacharier L, Bateman E, et a. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022; 205 (1): 17-35.
5. To T, Stanojevic S, Moores G, et a. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012; (12): 204.
6. Bakakors A, Loukides S, Usumani O, et a. Biologics in severe asthma: the overlap endotype - opportunities and challenges. Expert Opin Biol Ther. 2020; 20 (12): 1427-1434.
7. GEMA 5.0. Spanish guideline on the management of Asthma. 2021.
8. Larenas-Linneman D, Salas-Hernández J, Del Río-Navarro B, et al. MIA 2021, Integrated Management of Asthma: Guidelines for Mexico. Rev Alerg Mex. 2021; 68 (Suppl 1): 122.
9. Sívori M, Pascansky D. High T2 severe asthma: analysis of clinical trial design of new biologics. American Journal of Respiratory Medicine. 2022; 22 (1): 98-115.
10. Quirce S, Phillips-Angles E, Domínguez-Ortega J, Barranco P. Biologics in the treatment of severe asthma. Allergol Immunopathol (Madr). 2017; 45 (Suppl 1): 45-49.
11. Calzetta L, Matera M, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol. 2019; 15 (6): 517-520.
12. Bagnasco D, Heffler E, Testino E, et a. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opin Drug Metab Toxicol. 2019; 15 (2): 113-20.
13. Canonica G, Senna G, Mitchell P, et a. Therapeutic interventions in severe asthma. World Allergy Organ J. 2016; 9 (1): 40.
14. Ridolo E, Pucciarini F, Nizi M, et a. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother. 2020; 16 (10): 2349-56.
15. Pelaia C, Vatrella A, Bruni A, et a. Benralizumab in the treatment of severe asthma: design, development, and potential place in therapy. Drug Des Devel Ther. 2018; (12): 619-628.
16. Rupani H, Hew M. Super-Responders to severe asthma Treatments: Defining a New Paradigm. J Allergy Clin Immunol Pract. 2021; 9 (11): 4005-4006.
17. Basque-Navarre Society of Respiratory Pathology. svnpar.es. 2018. https://www.svnpar.es/wp-content/uploads/2018/11/Test_ACQ.pdf.
18. VADEMECUM. vademecum.es. 2020. https://www.vademecum.es/mexico/medicamento/1489566/fasenra-solucion-inyectable-en-jeringa-prellenada-30-mg-ml.
19. Juniper E, Guyatt G, Cox F, Ferrie P, King D. Development, and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999; 14 (1): 32-38.
20. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Available from: www.ginasthma.org.
21. Bakakos A, Rovina N, Bakakos P. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy. Int J Mol Sci. 2021; 22 (8): 3969.
22. Larenas-Linnemann D, Gochicoa-Rangel L, Macías-Weinmann A, et al. Mexican consensus regarding exhaled nitric oxide fraction in asthma. Rev Allerg Mex. 2020; 67 (Suppl 2): S1-S25.
23. Upham JW, Le Lievre C, Jackson DJ, et al. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. J Allergy Clin Immunol Pract. 2021; 9 (11): 3997-4004. doi:10.1016/j.jaip.2021.06.041
24. Miralles-López J, Andújar-Espinosa R, Bravo-Gutiérrez F, et a. Analysis of response of severe eosinophilic asthmatic patients to benralizumab. Allergol immunopathol. 2022; 50 (6): 163-168.
25. Kavanagh J, Hearn A, Dhariwal J, et a. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. 2021; 159 (2): 496-506.
26. Jackson D, Heaney L, Humbert M, et a. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomized multicenter. open-label, phase 4 study. Lancet. 2024; 403 (10423): 271-281.
27. Pelaia C, Busceti M, Crimi C, et a. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020; (129): 110444.
28. Vultaggio A, Aliani M, Altieri E, et a. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respir Res. 2023; 24 (1): 135.
29. FitzGerald J, Bleecker E, Nair P, et a. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128-2141.
30. Bleecker E, FitzGerald J, Chanez P, et a. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomized, multicenter, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115-2127.
31. Harrison T, Chanez P, Menzella F, et a. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomized, controlled, phase 3b trial. Lancet Respir Med. 2021; 19 (3): 260-274.
32. Busse W, Bleecker E, FitzGerald J, et a. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019; 7 (1).
33. Nair P, Wenzel S, Rabe K, et a. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376 (25): 2448-24-58.
34. Menzies-Gow A, Gurnell M, Heaney L, et a. Oral corticosteroid elimination via a personalized reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENT): a multicenter, open-label, single-arm study. Lancet Respir Med. 2022; 10 (1): 47-58.
35. Korn S, Bourdin A, Chupp G, et a. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021; 9 (12): 4381-4392.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 Revista Alergia México